Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.04.2024 | Case report

Dupilumab/steroids/tacrolimus

Conjunctivitis and lack of efficacy

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Licata G, et al. Efficacy and safeness of tralokinumab in patients with atopic dermatitis who developed conjunctivitis under dupilumab: A case series. Journal of the European Academy of Dermatology and Venereology 37: e1064-e1065, No. 8, Aug 2023. Available from: URL: 10.1111/jdv.19108 Licata G, et al. Efficacy and safeness of tralokinumab in patients with atopic dermatitis who developed conjunctivitis under dupilumab: A case series. Journal of the European Academy of Dermatology and Venereology 37: e1064-e1065, No. 8, Aug 2023. Available from: URL: 10.1111/jdv.19108
Metadaten
Titel
Dupilumab/steroids/tacrolimus
Conjunctivitis and lack of efficacy
Publikationsdatum
01.04.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-56819-4

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Leuprorelin

Case report

Testosterone

Case report

Multiple drugs